Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. August 2022 07:30 ET | Quelle: SciSparc Ltd

SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.

Results indicate significant decrease in cocaine craving in a sub-group that received the treatment TEL AVIV, Israel, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a...
02. Juni 2022 08:30 ET | Quelle: SciSparc Ltd

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields Another Patent Application for their Proprietary Psychedelic Combination to Treat Cocaine Addiction

No dedicated treatment currently available for cocaine addiction TEL AVIV, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical...
03. August 2021 07:00 ET | Quelle: Clearmind Medicine

Mark Haden, Psychedelic Medicine Expert, Joins Clearmind Medicine’s Advisory Board

Toronto, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of...
20. Juli 2021 07:00 ET | Quelle: Clearmind Medicine

Clearmind Issues Shareholder Letter

Toronto, July 20, 2021 (GLOBE NEWSWIRE) -- via InvestorWire-- Clearmind Medicine Inc. (CSE: CMND) ("Clearmind" or the "Company"), a psychedelic medicine biotech company focused on the discovery and...